Amneal Pharmaceuticals
Mid Cap · Healthcare · Drug Manufacturers - Specialty & Generic
$18.19+$0.04 (+0.22%)
Amneal Pharmaceuticals
Mid Cap · Healthcare · Drug Manufacturers - Specialty & Generic
$18.19+$0.04 (+0.22%)
Stock analysis
Get the AI take on AMRX
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$7.67
High$19.26
Today $18.19
RSI (14)
54.6Neutral
03070100
Overall score
66/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$16
Current price
$18.19
Median target
$21
Highest
$25
LowHigh
Operating Record
Revenue
What's working
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
- Price / sales: You're paying a modest amount for each dollar of revenue coming in.
What to watch
- Debt exceeds cash by $2.7B, increasing balance-sheet pressure, a warning sign.
- Price / FCF: Cash generation hasn't caught up to the price tag yet.
What the market charges
Forward P/E
Favorable · 17% below avg
18.28x
Price / sales
Strong · Priced modestly against the revenue it brings in
1.86x
Price / FCF
Rich · Priced far above what its cash flow currently supports
69.74x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
12.27x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
18.6%
ROE
Strong · Strong returns on shareholders' money
613.0%
Debt / equity
Rich · Carrying more debt than equity can comfortably absorb
23.87x
Current ratio
Strong · Comfortable room to cover bills due within a year
2.20x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $5.80B | 37.9 | +9.3% | 66 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |